Jingyi Li
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
Journal: The Journal of dermatological treatment
Published: July 15, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Journal: The Journal of dermatological treatment
Published: July 06, 2026
First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.
Journal: Frontiers in immunology
Published: February 14, 2026
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: November 05, 2025
Clinical practice guideline for H1 antihistamine-resistant Chronic Spontaneous Urticaria.
Journal: Asian Pacific journal of allergy and immunology
Published: November 03, 2025
52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 28, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.
Journal: International journal of dermatology
Published: September 24, 2025
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial.
Journal: The British journal of dermatology
Published: August 25, 2025
Study on the optimization of natural gas station inspection paths considering station priority.
Journal: Scientific reports
Published: August 12, 2025
Artificial intelligence in atopic dermatitis: Current applications and future perspectives.
Journal: Chinese medical journal
Published: August 06, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial.
Journal: Clinical and translational allergy
Published: July 24, 2025
Directed Crystallization: Engineering Facet-Specific High-Entropy Alloy Nanocatalysts Toward Advanced Zinc-Air Batteries.
Journal: Angewandte Chemie (International ed. in English)
Published: July 07, 2025
Last Updated: 09/26/2026